Carfostin is under clinical development by Asklepios BioPharmaceutical and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Carfostin’s likelihood of approval (LoA) and phase transition for Non-ischemic Cardiomyopathy took place on 28 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Carfostin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Carfostin overview

Carfostin (BNP-CHF) is under development for the treatment of advanced stage III/IV chronic heart failure and chronic non-ischemic cardiomyopathy. The drug candidate is a protein and cellular therapy based recombinant adeno-associated virus (rAAV) biological nanoparticle. The drug candidate is based on Biological Nano Particles (BNP) technology and Self-Complementary Vector technology. It targets protein phosphatase 1.

Asklepios BioPharmaceutical overview

Asklepios BioPharmaceutical (AskBio) is AAV gene therapy development company that develops and markets novel protein and cellular based therapies. Its product pipeline includes therapies for the treatment of neuromuscular, central nervous system, heart related diseases including pompe, limb-girdle 2i, huntington’s, epilepsy, parkinson’s, and congestive heart failure (nanocor). AskBio has developed library of AAV biological nano particles that provides unsurpassed transduction. It serves pharmaceutical and biotechnology companies. AskBio is headquartered in Durham, North Carolina, the US.

Quick View Carfostin LOA Data

Report Segments
  • Innovator
Drug Name
  • Carfostin
Administration Pathway
  • Intracoronary
Therapeutic Areas
  • Cardiovascular
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.